WESPAC Advisors SoCal’s Novartis NVS Stock Holding History

WESPAC Advisors SoCal’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,981	Closed	-$170K	–	226
2019 Q1	$170K	Hold	1,981	–	–	0.09%	90
2018 Q4	$152K	Hold	1,981	–	–	0.1%	88
2018 Q3	$152K	Buy	+1,981	New	+$146K	0.08%	94
2018 Q2	–	Sell	-2,037	Closed	-$147K	–	195
2018 Q1	$147K	Hold	2,037	–	–	0.09%	86
2017 Q4	$153K	Hold	2,037	–	–	0.09%	89
2017 Q3	$156K	Sell	2,037 -28	-1%	-$2.12K	0.09%	94
2017 Q2	$154K	Sell	2,065 -28	-1%	-$1.98K	0.1%	95
2017 Q1	$139K	Buy	2,093 +84	+4%	+$5.6K	0.09%	95
2016 Q4	$131K	Sell	2,009 -1,367	-40%	-$88.7K	0.08%	94
2016 Q3	$239K	Sell	3,376 -363	-10%	-$26.5K	0.16%	75
2016 Q2	$276K	Buy	3,739 +558	+18%	+$38.5K	0.18%	72
2016 Q1	$206K	Sell	3,181 -279	-8%	-$19K	0.15%	72
2015 Q4	$266K	Buy	+3,460	New	+$275K	0.18%	73

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

WESPAC Advisors SoCal's NVS Position: Q2 2019 in Review

WESPAC Advisors SoCal sold out of Novartis (NVS) in Q2 2019, closing a stake of 1,981 shares — an estimated $170K sold.

WESPAC Advisors SoCal first reported a position in NVS in Q4 2015 and held it in 13 quarters. The position peaked at $276K in Q2 2016. 1,094 funds tracked by Wall St. Rank hold NVS as of Q2 2019.

WESPAC Advisors SoCal reported no remaining Novartis position as of Q2 2019 after selling out during the quarter.
WESPAC Advisors SoCal sold 1,981 Novartis shares in Q2 2019, an estimated $170K.
WESPAC Advisors SoCal first reported a position in Novartis in Q4 2015 and held it in 13 quarters.
WESPAC Advisors SoCal's Novartis position peaked at $276K in Q2 2016.
1,094 funds tracked by Wall St. Rank held Novartis as of Q2 2019.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2019, filed 30 Jul 2019.